Dapagliflozin 10 mg (Generic)

Product Overview

Dapagliflozin 10 mg is an oral medication classified as a sodium‑glucose cotransporter‑2 (SGLT2) inhibitor. It is formulated by Healing Pharma, an Indian pharmaceutical company, and supplied in strips containing ten tablets. The product is intended for the management of type 2 diabetes mellitus when lifestyle modification alone is insufficient to achieve glycemic control. Each strip is packaged for convenience and contains a standardized 10 mg dose of dapagliflozin, a molecule that has been extensively studied for its ability to improve blood glucose levels while also offering cardiovascular and renal benefits. The medication is available in pack sizes of 100, 200, or 300 tablets, allowing patients to select a quantity that matches their treatment plan.

What is Dapagliflozin 10 mg

Dapagliflozin belongs to a class of drugs that block the SGLT2 protein in the proximal renal tubules, preventing glucose from being reabsorbed into the bloodstream. As a result, excess glucose is excreted in the urine, leading to a modest but clinically meaningful reduction in fasting and post‑prandial glucose concentrations. The 10 mg strength is the most commonly prescribed dose for adults with type 2 diabetes who do not have severe renal impairment. The drug is chemically described as a selective inhibitor of SGLT2, and its systemic exposure is measured in milligrams per liter, reflecting a dose that balances efficacy with tolerability. Generic versions, such as those produced by Healing Pharma, contain the same active ingredient and meet the same quality standards as reference products.

Uses and Benefits

The primary use of dapagliflozin 10 mg is to lower blood glucose in adults with type 2 diabetes mellitus, particularly when added to metformin or other oral antihyperglycemic agents. Clinical trials have demonstrated that the drug reduces HbA1c by approximately 0.5 to 0.8 percent units, a change that is considered clinically significant. Beyond glucose control, dapagliflozin has been shown to lower the risk of hospitalization for heart failure and to slow the progression of chronic kidney disease in patients with diabetes. These cardiovascular and renal advantages make the medication a valuable option for individuals who have additional risk factors such as hypertension or dyslipidemia. The once‑daily oral route supports adherence, and the fixed 10 mg dose simplifies dosing regimens for both patients and clinicians.

How It Works

Dapagliflozin exerts its effect by selectively inhibiting the SGLT2 transporter located in the early portion of the nephron. Normally, this transporter reabsorbs approximately 90 percent of filtered glucose back into the bloodstream. When the drug blocks this pathway, glucose is eliminated through urine, independent of insulin signaling. This mechanism operates continuously, providing a steady reduction in circulating glucose regardless of meal intake. The resulting glucosuria also contributes to modest weight loss, as the excreted glucose represents calories that are no longer retained. Additionally, the drug’s action on the renal vasculature helps to reduce intraglomerular pressure, which can alleviate stress on the kidneys over time.

Dosage Guidelines

The recommended starting dose of dapagliflozin for most adults with type 2 diabetes is one tablet of 10 mg taken once daily, with or without food. The dose may be adjusted based on renal function; patients with an estimated glomerular filtration rate (eGFR) below 45 mL/min/1.73 m² should consult a healthcare professional before initiating therapy, as the drug’s efficacy may be reduced. In cases of mild to moderate renal impairment, the standard 10 mg dose can still be used, but close monitoring of kidney function is advised. For patients with a history of hypoglycemia or those taking insulin or sulfonylureas, a lower dose may be considered to minimize the risk of low blood sugar. The tablet should be swallowed whole and stored at room temperature, away from moisture and heat.

Side Effects

Like all medications, dapagliflozin can cause adverse effects, although most are mild and transient. The most frequently reported side effects include urinary tract infections, genital mycotic infections, and increased urination. Some patients may experience dehydration or low blood pressure, especially when fluid intake is insufficient or when the drug is used in combination with diuretics. Rare but serious complications such as ketoacidosis have been documented, particularly in situations of prolonged fasting, surgery, or inadequate carbohydrate intake. Patients should be instructed to monitor for symptoms such as persistent nausea, vomiting, abdominal pain, or unusual fatigue, and to seek medical attention promptly if these occur. Reporting any unexpected reactions to a healthcare provider ensures timely management.

Warnings and Precautions

Before starting dapagliflozin, clinicians should assess a patient’s renal function, history of cardiovascular disease, and potential for ketoacidosis. The drug is contraindicated in individuals with severe renal impairment (eGFR < 30 mL/min/1.73 m²) or those undergoing dialysis without physician guidance. Patients with a prior incidence of diabetic ketoacidosis should use the medication with caution, as the risk may be heightened during periods of physiological stress. It is also advisable to avoid excessive alcohol consumption, as alcohol can exacerbate dehydration. Women who are pregnant or breastfeeding should not use dapagliflozin, and routine laboratory monitoring of kidney function and electrolytes is recommended during long‑term therapy. For additional scientific background, refer to the NIH’s overview of SGLT2 inhibitors (link).

Frequently Asked Questions

What is the typical dose of dapagliflozin 10 mg?

The usual dose is one tablet of 10 mg taken once daily, with or without food. Adjustments are made only after a clinician evaluates kidney function and the patient’s overall health.

Can dapagliflozin be used with insulin?

Yes, it can be combined with insulin, but clinicians often reduce the insulin dose to lower the chance of hypoglycemia, especially when the patient is also taking other glucose‑lowering agents.

Does the medication cause weight loss?

Dapagliflozin promotes modest weight loss by excreting excess glucose in urine, which reduces caloric retention. The amount varies among individuals and is not a primary purpose of the drug.

Is the drug safe for older adults?

Older adults can use dapagliflozin, but they may be more susceptible to dehydration and low blood pressure. Close monitoring and adequate fluid intake are recommended.

Where can I find more information about the drug?

Detailed prescribing information is available from the FDA label (link) and from reputable medical databases such as Drugs.com.

Related Products

• Tretinoin 0.025% Cream (TRETINOIN)
• Azelax Cream (Azelaic Acid)
• Tretinoin 0.1% Cream (Tretinoin)
• Tretinoin Cream
• Tretinoin 0.05% Cream (TRETINOIN)
• Accufine 40 mg (Isotretinoin)
• Accufine 30 mg (Isotretinoin)
• Tretiheal 0.025% Cream (Tretinoin)
• Tretiheal 0.05% Cream (Tretinoin)
• Tretiheal 0.1% Cream (Tretinoin)
• Accufine 5 mg (Isotretinoin)
• Accufine 20 mg Softgel Capsule (Isotretinoin)